ReviewMolecular neurobiology2025
The CCL17/CCL22-CCR4 Axis in Pain Pathogenesis: A Comprehensive Review of Immune-Mediated Mechanisms and Therapeutic Opportunities.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neuroimmune interactions: from molecular mechanisms to therapeutic targets.Molecular biomedicine · 2026Review
- Tet2 deficiency drives age-related heterogeneous progression of myeloid neoplasms through epigenetic-immune microenvironment imbalance.Journal of translational medicine · 2026Article
- Review
- Tumor microenvironment and key signaling pathways in breast cancer progression and therapy resistance: A review.Biomolecules & biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of C-C motif chemokine ligand (CCL) 17 and CCL22 signalling has been demonstrated in allergic disorders, such as asthma and atopic dermatitis, as well as multiple types of neoplastic disorders. New evidence has identified that CCL17/CCL22 activation of the receptor CCR4 functions to mediate pain, with distinct roles in arthritic, neuropathic, and inflammatory postoperative pain. CCR4 blockade is suggested to prevent the development of neuropathic pain by inhibiting microglia activation and the subsequent increase in pronociceptive cytokines. CCL17 can also play a key role in the pathophysiology of arthritic pain. Further, CCL17 expression is increased in response to granulocyte-macrophage colony-stimulating factor. Both CCL17 and CCL22, produced by skin-resident dendritic cells in response to incisional wounds, bind CCR4 expressed on peripheral sensory neurons, directly inducing pain signalling. These findings suggest that CCR4 may represent a therapeutic target for reducing pain. Understanding the role of CCR4 in the process of pain may also provide essential insight into the development of these therapeutic agents. The present paper provides a comprehensive review of the current literature on the role of the immune system in the inflammatory pain response, with a specific focus on the role of CCL17 and CCL22 activity in the pathophysiology of pain. Also, we discuss the potential for therapeutically targeting CCR4 and its clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.